Cite
HARVARD Citation
Qin, S. et al. (2021). Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet gastroenterology and hepatology. pp. 559-568. [Online].